Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.72 EUR
Change Today -0.03 / -3.98%
Volume 0.0
XOMA On Other Exchanges
As of 3:15 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

xoma corp (XOMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/27/14 - €4.66
52 Week Low
08/25/15 - €0.57
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for XOMA CORP (XOMA)

Related News

No related news articles were found.

xoma corp (XOMA) Related Businessweek News

No Related Businessweek News Found

xoma corp (XOMA) Details

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate includes gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, as well as diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. Its proprietary product pipeline also comprises XOMA metabolic activating, sensitizing, and deactivating/antagonizing antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, the company licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has collaboration and licensing agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; Symplmed Pharmaceuticals, LLC; and Texas A&M University. The company was founded in 1981 and is headquartered in Berkeley, California.

176 Employees
Last Reported Date: 08/10/15
Founded in 1981

xoma corp (XOMA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $569.5K
Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: $250.3K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $411.0K
Chief Commercial Officer and Vice President
Total Annual Compensation: $391.4K
Compensation as of Fiscal Year 2014.

xoma corp (XOMA) Key Developments

XOMA CORP. Pledges 30% Workforce Reduction

XOMA CORP. pledged a 30% workforce reduction on 19 August, 2015, resulting in the termination of 58 positions across all areas of the organization, leading to a workforce of 134 employees. XOMA completed this action on 21 August, 2015. Affected workers can receive severance payments and payments of their COBRA premiums for up to 9 months.

XOMA Corporation Seeks Acquisitions

XOMA Corporation (NasdaqGM:XOMA) is considering strategic options for it's manufacturing and biodefense operations.

XOMA Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

XOMA Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $2,539,000 against $75,973,000 a year ago. The reduction in 2015 revenues reflects lower activity under the company's existing contracts with National Institute of Allergy and Infectious Diseases (NIAID) for the development of anti-botulism agents. Loss from operations was $22,213,000 against $18,777,000 a year ago. Net loss was $23,759,000 or $0.20 per diluted share against $11,897,000 or $0.17 per diluted share a year ago. For the six months, the company reported total revenues of $5,190,000 against $9,383,000 a year ago. Loss from operations was $44,786,000 against $42,251,000 a year ago. Net loss was $45,477,000 or $0.39 per diluted share against $16,584,000 or $0.38 per diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:GR €0.72 EUR -0.03

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €10.26 EUR -0.05
BioInvent International AB kr2.75 SEK -0.04
Genmab A/S kr586.50 DKK -11.00
MorphoSys AG €61.18 EUR -2.04
PDL BioPharma Inc $5.65 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XOMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at